The disclosure provides methods for the selection and isolation of T cells expressing programmed cell death 1 (PD-1) and for selecting a PD-1 expression level of the isolated PD-1 expressing T cells. The disclosure also provides methods of large scale expansion of selected and isolated PD-1 expressing T cells, as well as methods for treating a subject comprising administering selected and isolated PD-1 expressing T cells to the subject.

[Problem to be Solved] To provide a compound for removing pluripotent cells from a cell population potentially containing the pluripotent cells. [Solution] A polyphenylalanine derivative is contacted with a cell population of interest.

Disclosed herein are cell processing systems, devices, and methods thereof. A system for cell processing may comprise a plurality of instruments each independently configured to perform one or more cell processing operations upon a cartridge, and a robot capable of moving the cartridge between each of the plurality of instruments.

A method for bioprocessing includes the steps of providing a bioprocessing system having a first bioreactor vessel and a second bioreactor vessel, activating a population of cells in the first bioreactor vessel, genetically modifying the population of cells to produce a population of genetically modified cells, and expanding the population of genetically modified cells within the first bioreactor vessel and the second bioreactor vessel.

A therapeutic serum suitable for inclusion in a cosmetic preparation may be produced by stressing a co-culture including proliferative cells. The co-culture of cells may be obtained by growing first culture to less than one-hundred percent confluence on a surface. After a monolayer of first culture is established, a second culture may be seeded onto at least one cell free area on the surface, the resulting co-culture grown to less than one-hundred percent confluence. Additional cultures may then be seeded onto cell free areas of the surface and established until a monolayer having the desired population of cells is obtained. The monolayer is then stressed to obtain a serum by conditioning a collection medium. The obtained serum may be combined with a suitable cosmetic base to provide a cosmetic preparation.

An antibody that binds a glycosylated protein is disclosed, wherein the glycosylation comprises the glycan motif Fuc1-2Gal1-3GlcNAc1-3Gal1 or Fuc1-2Gal1-3GlcNAc. Antibodies that are cytotoxic against undifferentiated pluripotent cells are also disclosed.

A method is directed to separating contaminants from mammalian cells in an aqueous multiphase system, and includes loading a container with a liquid having a top liquid phase and a bottom liquid phase. A cover medium is inserted in the container with a mixture of cultured mammalian cells and contaminants. The container is incubated and centrifuged for respective periods of time. In response to the centrifuging, the cells are separated from the contaminants in accordance with the respective density of the cells, the contaminants, and each liquid phase, resulting in the cells being located at a liquid-to-liquid interface between the top liquid phase and the bottom liquid phase and the contaminants being located at the bottom of the container.

In the context of a stem cell-based therapy in which differentiated cells are derived from pluripotent stem cells, this application discloses approaches for eliminating residual pluripotent stem cells that may remain in a batch of differentiated progeny cells. This advantageously prevents the formation of teratoma tumors when the differentiated cells are eventually used for the therapy. This can be accomplished by exposing the batch of differentiated progeny cells and the residual pluripotent stem cells to an alternating electric field for a period of time. The frequency and field strength of the alternating electric field are such that the pluripotent stem cells die off as a result of exposure to the alternating electric fields, while the differentiated cells remain substantially unharmed. This results in a purified batch of differentiated progeny cells that is rendered safe for use in the stem cell-based therapy.

The present invention concerns enriched heterogeneous mammalian renal cell populations characterized by biomarkers, and methods of making and using the same.

A cell sorting method includes: obtaining a cervical sample of a pregnant mammal, the cervical sample including placental trophoblast cells and cervical cells; removing the mucus of the cervical sample; dispersing the placental trophoblast cells and the cervical cells; centrifuging the cervical sample to remove the supernatant of the cervical sample; and using a dielectrophoretic chip to perform sorting on the cervical sample, so as to sort out the placental trophoblast cells from the cervical cells.